TY -的T1 - Utility-Weighted改良Rankin范围:推导和应用程序来完成中风试验(P5.008) JF -神经学乔-神经学六世- 82 - 10补充SP - P5.008盟Napasri Chaisinanunkul AU -杰首页弗里节省盟都铎Jovin盟-斯科特·贝瑞AU -罗杰·刘易斯AU -肯尼迪李盟-安东尼可•福尔兰正AU -布莱斯巴克斯特盟-希勒米Lutsep AU - Marc日博盟-康Jansen盟圣人Gupta AU -康Pereira-Mendes盟劳尔Nogueira Y1 - 2014/04/08 UR - //www.ez-admanager.com/content/82/10_Supplement/P5.008.abstract N2 -目的:获得,和性能的评估,Utility-Weighted版本的改良Rankin规模(夫人)评估全球残疾。背景:夫人是最普遍采用的主要终点急性中风试验,但它的力量是有限的,当分析以一分为二的方式和解释能力有限,当以顺序的方式进行了分析。加权7兰金水平公用事业规模可以提高精度,将从任意排列间距固定的间隔距离,直接反映病人和社会的估值结果残疾状态。实用程序设计/方法:加权平均(UW-mRS)导出了二夫人值从病人以人群为基础的研究和卫生专业人员在person-tradeoff研究。结果UW-mRS、标准顺序夫人,夫人一分为二在0 - 1,0,0 - 4被应用于13日试验和结果急性中风的治疗通常被认为是有益的。结果:效用值:mrs0 - 1.0;mrs1 - 0.91;mrs2 - 0.76;mrs3 - 0.65;mrs4 - 0.33; mRS5-0; mRS6-0. Mean outcome utilities were nominally higher in the intervention arm in all 13 treatment comparisons, except treatment with IV TPA in the 4.5-6h window. The UW-mRS generally paralleled the ordinal mRS in power, except when treatment effects were bidirectional (both benefit and harm). Among all comparisons of >3h interventions for large ischemic strokes, the UW-mRS, ordinal mRS, and dichotomized 0-2 were each positive in 3 of 5 trials, and dichotomized 0-1 and 0-4 each positive in 2 of 5. The UW-mRS, similar to the ordinal, showed superior power to dichotomized analyses when treatment benefits accrued at multiple health state transitions, and less power when treatment effects concentrated at a single health state transition. CONCLUSIONS: A utility-weighted mRS performs similarly to the standard ordinal mRS in detecting treatment effects in actual stroke trials and in ensures the quantitative outcome is a valid reflection of patient-centered benefits. Study Supported by:Disclosure: Dr. Chaisinanunkul has nothing to disclose. Dr. Saver has received personal compensation for activities with the University of California, BrainsGate, CoAxia, ev3, Talecris, PhotoThera, Sygnis, and Stryker. Dr. Saver has received research support from the University of California, and the National Institutes of Health. Dr. Jovin has received personal compensation for activities with Covidein, Concentric Medical Inc., Stryker, and Silk Road Medical. Dr. Jovin has received personal compensation in an editorial capacity for Journal of Neuroimaging. Dr. Berry has received personal compensation for activities with Stryker. Dr. Lewis has received personal compensation for activities with Stryker. Dr. Lees has received personal compensation for activities with Stryker. Dr. Lees has received research support from various companies and funding bodies. Dr. Furlan has received personal compensation for activities with NMT Medical Boston, Forest Laboratories, Inc., Bristol-Meyers Squibb Company, Stryker, and Sanofi-Aventis Pharmaceuticals. Dr. Baxter has received personal compensation for activities with Stryker. Dr. Lutsep has received personal compensation for activities with Concentric Medical, Stryker, Co-Axia and AGA Medical. Dr. Lutsep has received personal compensation in an editorial capacity for the eMedicine Neurology Journal, Dr. Ribo has received personal compensation for activities with Stryker. Dr. Jansen has received personal compensation for activities with Stryker. Dr. Gupta has received personal compensation for activities with Stryker Neurovascular, Rapid Medical, and Covidien. Dr. Gupta has received personal compensation in an editorial capacity with the Journal of Neuroimaging, and Interventional Neurology. Dr. Pereira-Mendes has received personal compensation for activities with Stryker. Dr. Nogueira has received personal compensation for activities with Concentric Medical, Inc., ev3 Neurovascular, Inc., Coaxia, Inc., and Rapid Medical, Inc.Wednesday, April 30 2014, 3:00 pm-6:30 pm ER -